异甘草酸镁注射液治疗AIH-PBC重叠综合征的临床疗效及安全性  

Clinical efficacy and safety of magnesium isoglycyrrhizinate injection in the treatment of AIH-PBC overlap syndrome

作　　者：徐璐 邵锦敏 周兴蓓 蒋亚萍 XU Lu;SHAO Jinmin;ZHOU Xingbei;JIANG Yaping(The Third People′s Hospital of Zhenjiang,Jiangsu Province,Zhenjiang 212000,China)

机构地区：[1]江苏省镇江市第三人民医院,212000

出　　处：《临床合理用药杂志》2023年第4期15-19,共5页Chinese Journal of Clinical Rational Drug Use

基　　金：江苏大学临床医学科技发展基金(JLY20180059)。

摘　　要：目的观察异甘草酸镁注射液治疗自身免疫性肝炎—原发性胆汁性胆管炎(AIH-PBC)重叠综合征的临床疗效及安全性。方法选取2016年5月—2019年5月江苏省镇江市第三人民医院收治的AIH-PBC重叠综合征患者84例,采用随机数字表法分为试验组和对照组,每组42例。对照组患者给予熊去氧胆酸胶囊联合醋酸泼尼松龙片治疗,试验组患者在对照组治疗基础上给予异甘草酸镁注射液治疗,2组均连续治疗4周。比较2组患者临床疗效、肝功能指标、肝纤维化指标、免疫功能指标、凝血酶原时间(PT)、血流指标、电解质指标、尿素氮(BUN)水平及药物不良反应。结果试验组患者总有效率为92.86%,高于对照组的69.05%,差异有统计学意义(χ^(2)=7.721,P=0.005)。治疗4周后,2组患者的肝功能指标、肝纤维化指标、免疫功能指标等均优于治疗前,且试验组部分指标优于对照组,差异均有统计学意义(P<0.05);随访4周,试验组患者的肝功能指标、肝纤维化指标及部分免疫功能指标和血流指标均优于对照组(P<0.05);治疗4周后及随访4周,2组患者的电解质指标及BUN水平均无显著变化(P>0.05)。2组患者的不良反应总发生率均为9.52%,差异无统计学意义(P>0.05)。结论异甘草酸镁注射液治疗AIH-PBC重叠综合征具有良好的临床疗效,可有效促进肝功能恢复,减轻肝纤维化,改善免疫功能,且安全可靠。Objective To observe the clinical efficacy and safety of magnesium isoglycyrrhizinate injection in the treatment of autoimmune hepatitis primary biliary cholangitis(AIH-PBC)overlap syndrome.Methods 84 AIH-PBC overlap syndrome patients admitted to the Third People′s Hospital of Zhenjiang,Jiangsu Province from May 2016 to May 2019 were selected and divided into test group and control group with 42 patients in each group by random number table.The patients in the control group were treated with ursodeoxycholic acid capsule combined with prednisolone acetate tablets.The patients in the test group were treated with magnesium isoglycyrrhizinate injection on the basis of the treatment in the control group,both groups were treated continuously for 4 weeks.The clinical efficacy,liver function index,liver fibrosis index,immune function index,prothrombin time(PT),blood flow index,electrolyte index,urea nitrogen(BUN)level and adverse drug reactions were compared between the two groups.Results The total effective rate of patients in the test group was 92.86%,higher than 69.05%in the control group,with a statistically significant difference(χ^(2)=7.721,P=0.005).After 4 weeks of treatment,the indexes of liver function,liver fibrosis and immune function of patients in both groups were better than those before treatment,and some indexes in the test group were better than those in the control group,with statistically significant differences(P<0.05);After 4 weeks of follow-up,the indexes of liver function,liver fibrosis,partial immune function and blood flow in the test group were better than those in the control group(P<0.05);After 4 weeks of treatment and 4 weeks of follow-up,the electrolyte index and BUN level of the two groups had no significant changes(P>0.05).The total incidence of adverse reactions in the two groups was 9.52%,with no significant difference(P>0.05).Conclusion Magnesium isoglycyrrhizinate injection has a good clinical effect in the treatment of AIH-PBC overlap syndrome,which can effectively promote the reco

关 键 词：AIH-PBC重叠综合征 异甘草酸镁注射液 临床疗效 安全性 

分 类 号：R969.3[医药卫生—药理学]